<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749112</url>
  </required_header>
  <id_info>
    <org_study_id>HE08-004</org_study_id>
    <nct_id>NCT00749112</nct_id>
  </id_info>
  <brief_title>Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias</brief_title>
  <official_title>Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of low doses of alemtuzumab
      and rituximab are effective in the treatment of patients with autoimmune cytopenias who has
      failed on steroids, relapsed after steroids withdrawal or required continuous steroids
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune cytopenias are a common entities with good responses to steroids therapies as
      first line, but there is a considerable percentage of patients who relapse, become refractory
      or dependant on steroids to maintain an acceptable level of hemoglobin or platelets, and the
      treatment becomes more difficult increasing the secondary effects. The current study
      evaluates the safety and efficacy of the combination of low doses of alemtuzumab (anti CD52)
      and Rituximab (anti CD 20) as a second line treatment option for this subset of patients
      improving the cytopenias without increasing the adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (CR: complete remission, PR: partial remission, relapse rate.</measure>
    <time_frame>1, 2, 4 and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <condition>Anemia, Hemolytic, Autoimmune</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab, Rituximab</intervention_name>
    <description>Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>campath</other_name>
    <other_name>mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt; or = 16 years

          -  Weight: more than 40 Kg

          -  Autoimmune Hemolytic anemia with clinical and biochemical evidence of hemolysis
             refractory to treatment, in relapse or steroids dependant

          -  Idiopathic thrombocytopenic purpura with platelet counts &lt; 50,000, refractory to
             treatment, in relapse or steroids dependant

        Exclusion Criteria:

          -  Current viral or bacterial infection.

          -  Positive serology for HIV, HCV, HBV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gomez-Almaguer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>David Gomez-Almaguer</name_title>
    <organization>Hospital Universitario Dr. Jose E. Gonzalez</organization>
  </responsible_party>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hemolytic</keyword>
  <keyword>Autoimmune</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

